完整標題： Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals 發稿單位：美國FDA 發稿時間：March 29, 2022 撰 稿 者：美國FDA 原文連結：https://bit.ly/3wMHcv2 FDA在今日(3/29)核准輝瑞BNT和莫德納的第二追加劑(second booster dose) 施打的目標對象群是長者跟特定的免疫力低下族群 之前FDA已經核准了一劑追加劑，施打在已施打完基礎加強劑的目標群上 本次核准透過施打第二追加劑， 將能夠對那些重症高危險群提供更多的免疫保護力，避免重症住院甚至死亡。 目前的證據指出第二追加劑可以提供更高的保護力，無任何新的安全疑慮。 Today, the U.S. Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals. The FDA previously authorized a single booster dose for certain immunocompromised individuals following completion of a three-dose primary vaccination series. This action will now make a second booster dose of these vaccines available to other populations at higher risk for severe disease, hospitalization and death. Emerging evidence suggests that a second booster dose of an mRNA COVID-19 vaccine improves protection against severe COVID-19 and is not associated with new safety concerns. 可接受施打的對象(疫苗標準參照美國FDA/CDC標準)： 1.50歲以上的成年人 且完成第一次追加劑接種4個月後 2.曾因為接受器官移植等造成免疫力低下 且完成第一次追加劑接種4個月後 (輝瑞BNT年齡12歲以上、莫德納18歲以上) The agency amended the emergency use authorizations as follows: A second booster dose of the Pfizer-BioNTech COVID-19 Vaccine or Moderna COVID-19 Vaccine may be administered to individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine. A second booster dose of the Pfizer-BioNTech COVID-19 Vaccine may be administered to individuals 12 years of age and older with certain kinds of immunocompromise at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine. These are people who have undergone solid organ transplantation, or who are living with conditions that are considered to have an equivalent level of immunocompromise. A second booster dose of the Moderna COVID-19 Vaccine may be administered at least 4 months after the first booster dose of any authorized or approved COVID-19 vaccine to individuals 18 years of age and older with the same certain kinds of immunocompromise. (其餘段落省略) --

※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 220.129.233.152 (臺灣) ※ 文章網址: https://webptt.com/m.aspx?n=bbs/nCoV2019/M.1648571184.A.2A7.html